HK Stock Market Move | CLOVER BIO-B (02197) surged over 9% in early trading as Clover's respiratory combined vaccine received positive data from Phase II trials in Australia.

11:04 09/09/2026

Sanyeco-B (02197) rose over 9% in early trading. As of the time of writing, it has increased by 7.62%, trading at HKD 2.26, with a transaction volume of HKD 10.41 million.

CLOVER BIO-B (02197) surged over 9% in early trading. As of the time of writing, it rose 7.62%, reaching HKD 2.26, with a trading volume of HKD 10.41 million. In terms of news, on September 7, Clover Biologics announced that SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) showed positive preliminary data in a Phase II clinical trial conducted on elderly individuals aged 60-85 in Australia. A total of 420 subjects were enrolled in the trial, and after 28 days of vaccination, RSV neutralizing antibodies increased approximately 6-9 times, while hMPV neutralizing antibodies rose about 6-8 times, with no severe adverse events related to the vaccine reported; the company also completed a 2000-liter scale-up for commercial production. CEO Liang Guo stated that the positive results of this clinical trial significantly reduce the risks of future late-stage development and also validate the company's capabilities in developing multivalent protein respiratory vaccines using its differentiated Trimer-Tag platform.

Yuanyu Securities: The expansion of industrial gas volume combined with shareholder synergy leads to simultaneous improvements in gross margin and debt quality, assigning a "Buy" rating to BINHAI INV (02886).

HK Stock Market Move | GLOBAL NEW MAT (06616) rose nearly 4% in the morning, with the German business segment performing impressively in the first half of the year, and the effects of mergers and integration gradually becoming apparent.

HK Stock Market Move | AXERA (00600) rose over 10% as the company officially entered the Hong Kong Stock Connect and recently launched the M9 series of high-end intelligent driving chips.